Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Artiva Biotherapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q1 2025 to Q3 2025.
Artiva Biotherapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2025 was 13.5 %.
Debt-to-equity, Quarterly (%)
Artiva Biotherapeutics, Inc. Quarterly Debt-to-equity (%)
Period
Value
YoY Chg
Change %
Date
Q3 2025
13.5
Sep 30, 2025
Q2 2025
12.8
Jun 30, 2025
Q1 2025
33
Mar 31, 2025
* An asterisk sign (*) next to the value indicates that the value is likely invalid.
We use cookies and similar technologies to provide certain features, enhance
the user experience and deliver content that is relevant to your interests.
Depending on their purpose, analysis and marketing cookies may be used in
addition to technically necessary cookies. By clicking on "Agree and
continue", you declare your consent to the use of the aforementioned cookies.
Here
you can make detailed settings or revoke your consent (in part if necessary)
with effect for the future. For further information, please refer to our
Privacy Policy
.